<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Eli Lilly &amp; Company</title>
	<atom:link href="http://www.stockbloghub.com/tag/eli-lilly-co/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(AMGN) Amgen&#8217;s Vectibix Offers Mixed Data From Trial</title>
		<link>http://www.stockbloghub.com/2009/09/24/amgn-amgens-vectibix-offers-mixed-data-from-trial/16024</link>
		<comments>http://www.stockbloghub.com/2009/09/24/amgn-amgens-vectibix-offers-mixed-data-from-trial/16024#comments</comments>
		<pubDate>Thu, 24 Sep 2009 20:20:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16024</guid>
		<description><![CDATA[Yesterday, Amgen (AMGN) presented data from a phase III trial of its Vectibix in combination with Folfiri (an irinotecan based chemotherapy) as a second-line treatment for metastatic colorectal cancer at the 2009 ECCO 15 &#8211; ESMO 34 European Multidisciplinary Congress in Berlin. In the trial, Vectibix significantly improved progression-free survival (PFS) in patients with tumors containing a specific gene known as KRAS. Tumor KRAS status was confirmed in 91% of the 1,186 patients enrolled in the trial, the highest number ever reported for a second-line trial. The combination treatment of Vectibix and Folfiri achieved the co-primary endpoint by improving the median PFS by 2 months (5.9 months versus 3.9 months) compared to Folfiri alone. The combination also showed significant improvement (35% versus 10%) in tumor response rate in patients. However, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/24/amgn-amgens-vectibix-offers-mixed-data-from-trial/16024/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis and Regeneron Pharmaceuticals Suffer Late-stage Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2009/09/14/sny-sanofi-aventis-and-regeneron-pharmaceuticals-suffer-late-stage-pipeline-setback/15129</link>
		<comments>http://www.stockbloghub.com/2009/09/14/sny-sanofi-aventis-and-regeneron-pharmaceuticals-suffer-late-stage-pipeline-setback/15129#comments</comments>
		<pubDate>Mon, 14 Sep 2009 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15129</guid>
		<description><![CDATA[On Friday, Sanofi-Aventis (SNY) and collaboration partner, Regeneron Pharmaceuticals (REGN) suffered a pipeline setback with the companies halting development of their late-stage pipeline candidate, aflibercept, for the treatment of pancreatic cancer. Aflibercept, an anti-angiogenesis agent being developed for a variety of tumor types, was in a phase III study, which was evaluating the efficacy of the drug in combination with Eli Lilly’s (LLY) Gemzar (gemcitabine) versus placebo plus Gemzar for the first-line treatment of pancreatic cancer. A planned interim efficacy analysis of the study, carried out by an independent data monitoring committee, showed that the addition of aflibercept to Gemzar would not lead to a statistically significant improvement in the primary endpoint of overall survival compared to the placebo plus Gemzar combination. The companies will conduct a detailed analysis of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/14/sny-sanofi-aventis-and-regeneron-pharmaceuticals-suffer-late-stage-pipeline-setback/15129/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Amylin Pharmaceuticals Collaborates with Biocon</title>
		<link>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973</link>
		<comments>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:16:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14973</guid>
		<description><![CDATA[Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes. This agreement should ensure the optimum utilization of the synergistic capabilities of both the companies. Both companies have a strong focus on the development of treatments for diabetes. While Amylin&#8217;s &#8220;phybrid&#8221; technology will be used for the development of the candidate, Biocon will use its know-how in recombinant microbial expression to manufacture the compound. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. As per the terms of the agreement, development costs will be shared by the companies. Other details were not provided. The identification ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Drug Under FDA Review</title>
		<link>http://www.stockbloghub.com/2009/09/04/bmy-bristol-myers-squibb-drug-under-fda-review/14451</link>
		<comments>http://www.stockbloghub.com/2009/09/04/bmy-bristol-myers-squibb-drug-under-fda-review/14451#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:32:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14451</guid>
		<description><![CDATA[Yesterday, Bristol-Myers Squibb Company (BMY) announced the acceptance of a biologic license application (BLA) for belatacept by the U.S. Food and Drug Administration (FDA). The candidate is in late-stage development for treating kidney transplant patients. The agency has set May 1, 2010, as the Prescription Drug User Fee Act (PDUFA) action date. The biological product is being developed internally and is a fusion protein with novel immunosuppressive activity targeted to prevent solid organ transplant rejection. The company owns a patent covering belatacept as a composition of matter which expires in the U.S. in 2021. We believe that the candidate can prove to be a suitable alternative for transplant patients in this market with huge unmet medical needs. The market encompasses therapies that must be taken lifelong, ensuring a steady stream ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/bmy-bristol-myers-squibb-drug-under-fda-review/14451/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Huge Healthcare Fraud Penalty for Pfizer</title>
		<link>http://www.stockbloghub.com/2009/09/03/pfe-huge-healthcare-fraud-penalty-for-pfizer/14388</link>
		<comments>http://www.stockbloghub.com/2009/09/03/pfe-huge-healthcare-fraud-penalty-for-pfizer/14388#comments</comments>
		<pubDate>Thu, 03 Sep 2009 23:42:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14388</guid>
		<description><![CDATA[The world’s largest drugmaker Pfizer (PFE) now leads the list of largest healthcare fraud settlement payers. The company yesterday announced that it finalized with the U.S. Department of Justice (DoJ) to pay a total of $2.3 billion in penalty. The penalty is related to its off-label promotional practices for Bextra, and other fraudulent marketing practices for the promotion of four drugs. Pfizer also entered into an integrity agreement with the Health and Human Services Department under which it has agreed to ensure proper checks for a period of five years in order to avoid such issues. In 2005, Bextra was voluntarily withdrawn from the market as it was illegally promoted for several unapproved indications and dosages. In order to resolve the matter, Pfizer agreed to pay a criminal fine of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/pfe-huge-healthcare-fraud-penalty-for-pfizer/14388/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Dainippon Sumitomo Pharma Acquires Sepracor</title>
		<link>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333</link>
		<comments>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333#comments</comments>
		<pubDate>Thu, 03 Sep 2009 20:46:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14333</guid>
		<description><![CDATA[Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion. The market was abuzz with rumors yesterday regarding the potential takeover. The rumors led to a 26.46% increase in Sepracor’s stock price. Trading was halted in the afternoon with Sepracor shares closing at $22.80. This acquisition is the latest in a series of deals conducted by Japanese companies that are looking to tap the U.S. pharmaceutical market – the biggest in the world. Last year, we saw four such deals take place including Eisai’s acquisition of MGI Pharma, Takeda’s acquisition of Millennium Pharma and Shionogi’s acquisition of Sciele. Finally, Daiichi-Sankyo acquired a stake ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Completes Acquisition</title>
		<link>http://www.stockbloghub.com/2009/09/02/bmy-bristol-myers-squibb-completes-acquisition/14191</link>
		<comments>http://www.stockbloghub.com/2009/09/02/bmy-bristol-myers-squibb-completes-acquisition/14191#comments</comments>
		<pubDate>Wed, 02 Sep 2009 19:38:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14191</guid>
		<description><![CDATA[Bristol-Myers Squibb Co. (BMY) yesterday announced the completion of the $2.4 billion acquisition of Medarex, Inc.  Following the completion of the deal, Medarex has become a wholly-owned subsidiary of Bristol-Myers. The deal was funded by Bristol-Myers from available cash. The merger became effective on Sept 1. Consequently, the acquired entity will not trade on the Nasdaq Stock Market from Sept 2. As a reminder, Bristol-Myers initiated a cash tender offer to buy all outstanding shares of common stock of Medarex for $16.00 per share on July 28. The period expired on Aug 26 and the subsequent offering period ended on Aug 31. Approximately 90.7% of Medarex’s outstanding shares were tendered in favor of Bristol’s cash tender offer. Bristol-Myers acquired the remaining outstanding shares of Medarex common stock through a “short ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/bmy-bristol-myers-squibb-completes-acquisition/14191/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Drug Stomps Plavix</title>
		<link>http://www.stockbloghub.com/2009/09/01/azn-astrazenecas-brilinta-drug-stomps-plavix/14006</link>
		<comments>http://www.stockbloghub.com/2009/09/01/azn-astrazenecas-brilinta-drug-stomps-plavix/14006#comments</comments>
		<pubDate>Tue, 01 Sep 2009 17:32:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services,]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14006</guid>
		<description><![CDATA[AstraZeneca (AZN) recently said that results from a phase III head-to-head trial showed that its Brilinta (ticagrelor) achieved greater efficacy in the primary endpoint, reduction of cardiovascular events, compared to Sanofi-Aventis (SNY)/Bristol-Myers’ (BMY) Plavix (clopidogrel). Brilinta significantly reduced the mortality rate from cardiovascular events, myocardial infarctions and strokes without increasing major bleeding, which is a side-effect of Plavix. However, the frequently reported side-effects of Brilinta included slower heart rhythms and dyspnoea. Brilinta is an investigational oral anti-platelet treatment being developed for acute coronary syndrome (ACS). Results from the 18,624 patient PLATO (A Study of Platelet Inhibition and Patient Outcomes) trial were presented at the European Society of Cardiology congress and published in the New England Journal of Medicine (NEJM). The data on Brilinta look compelling and could help the product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/azn-astrazenecas-brilinta-drug-stomps-plavix/14006/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Wider Label Approval for Bristol Myers Squibb Drug</title>
		<link>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696</link>
		<comments>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696#comments</comments>
		<pubDate>Fri, 28 Aug 2009 00:18:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13696</guid>
		<description><![CDATA[Bristol Myers Squibb Co. (BMY) yesterday announced the approval of a broader label for its rheumatoid arthritis drug Orencia by the U.S. Food and Drug Administration (FDA). The agency approved an addition to the label that supports the use of Orencia (abatacept) in patients suffering from moderate to severe rheumatoid arthritis, duration of which is less than or equal to two years. The drug that recorded global sales of $129 million in 2008 is designed to reduce symptoms of rheumatoid arthritis. However, it should not be administered along with tumor necrosis factor (TNF) antagonists and is not recommended for use in tandem with other biologic rheumatoid arthritis therapies. As a reminder, the drug was initially approved by the FDA in late 2005 and made commercially available in the U.S. in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/bmy-wider-label-approval-for-bristol-myers-squibb-drug/13696/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Notified Johnson &amp; Johnson Intends to Stop Development of Risperidone</title>
		<link>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717</link>
		<comments>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717#comments</comments>
		<pubDate>Thu, 27 Aug 2009 23:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13717</guid>
		<description><![CDATA[On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson &#38; Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International stating that Janssen does not intend to continue with the development of the four-week long-acting injectable formulation of risperidone. A phase I study with the four-week formulation had been initiated in January 2009. Risperidone, which is marketed as Risperdal Consta, is Alkermes’ lead product. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). Risperdal Consta uses Alkermes&#8217; proprietary Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. The product is approved in more than 85 countries worldwide and is available in 60 countries. Risperdal Consta is superior to the first-generation Risperdal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb&#8217;s Plavix Patent Getting Review</title>
		<link>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837</link>
		<comments>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837#comments</comments>
		<pubDate>Thu, 20 Aug 2009 17:57:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PowerShares Autonomic Gr NFA Glbl Asset]]></category>
		<category><![CDATA[PTO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12837</guid>
		<description><![CDATA[Bristol-Myers Squibb (BMY) announced that its lead drug, Plavix, will be reviewed by the U.S. Patent and Trademark Office (PTO). Plavix is indicated for the reduction of the risk of heart attacks or strokes in patients with atherosclerosis (the build-up of plaque and hardening of the arteries). The drug is co-promoted with pharmaceutical giant Sanofi-Aventis (SNY). Plavix sales in the second quarter were $1,539 million, up 11%. Sales in 2008 were up 18% to $5.6 billion, making it one of the world’s best-selling pharmaceutical products. The patent of the antiplatelet blood thinner is expected to expire in November 2011, although the companies might win a six-month extension for conducting pediatric studies. Canada-based Apotex has requested the U.S. Patent and Trademark Office to review the patent as the company is looking to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/bmy-bristol-myers-squibbs-plavix-patent-getting-review/12837/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Mixed Results for Amgen&#8217;s Vectibix</title>
		<link>http://www.stockbloghub.com/2009/08/19/amgn-mixed-results-for-amgens-vectibix/12659</link>
		<comments>http://www.stockbloghub.com/2009/08/19/amgn-mixed-results-for-amgens-vectibix/12659#comments</comments>
		<pubDate>Wed, 19 Aug 2009 22:50:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12659</guid>
		<description><![CDATA[Yesterday, Amgen Inc. (AMGN) reported mixed top-line results from a phase III study evaluating Vectibix in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment for metastatic colorectal cancer (mCRC). The trial had two primary endpoints &#8211; progression-free and overall survival. Results showed that Vectibix, in combination with FOLFIRI, significantly improved progression-free survival (compared to FOLFIRI alone) in mCRC patients with tumors harboring the wild-type or un-mutated forms of KRAS. KRAS is a protein, which plays an important role in cell growth regulation. While the results were numerically greater, the Vectibix arm failed to achieve statistical significance. Meanwhile, the addition of Vectibix did not have any effect on the progression-free or overall survival in patients with tumors harboring the mutated form of KRAS. Earlier this month, Amgen presented positive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/amgn-mixed-results-for-amgens-vectibix/12659/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Lilly Discontinues Arzoxifene Trials</title>
		<link>http://www.stockbloghub.com/2009/08/19/lly-lilly-discontinues-arzoxifene-trials/12728</link>
		<comments>http://www.stockbloghub.com/2009/08/19/lly-lilly-discontinues-arzoxifene-trials/12728#comments</comments>
		<pubDate>Wed, 19 Aug 2009 21:43:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12728</guid>
		<description><![CDATA[Yesterday, Eli Lilly and Company (LLY) announced that it will not seek approval from the U.S. Food and Drug Administration (FDA) for its phase III pipeline candidate, arzoxifene, which is being developed for the prevention and treatment of osteoporosis in postmenopausal women and the reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis or low bone mass. The company released initial results from a pivotal, five-year, phase III study (GJAD GENERATIONS) which showed that arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women. However, the study failed to meet its main secondary efficacy endpoints. The candidate failed to show a statistically significant difference in endpoints like non-vertebral fractures, clinical vertebral fractures, cardiovascular events and cognitive function, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/lly-lilly-discontinues-arzoxifene-trials/12728/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072</link>
		<comments>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072#comments</comments>
		<pubDate>Tue, 09 Jun 2009 18:48:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8072</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043</link>
		<comments>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043#comments</comments>
		<pubDate>Mon, 08 Jun 2009 22:05:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8043</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Drug Companies: A Powerhouse of Profits</title>
		<link>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849</link>
		<comments>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849#comments</comments>
		<pubDate>Sat, 09 May 2009 23:36:21 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=6849</guid>
		<description><![CDATA[by The Investment U Research Team A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost of $8 billion. The other a study that finds more Americans than ever are taking some sort of prescription for mental illness – 73% more than in 1996. What’s interesting, apart from the fact that we seem to be overmedicating as a society, is that the numbers of patients and the costs of treatments spell hundreds of billions in profits for healthcare and drug makers. Taking a look at the eleven largest, we find that their market caps total almost $900 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IBM) Stock Market News for April 20, 2009 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2009/04/20/ibm-stock-market-news-for-april-20-2009-market-news/5769</link>
		<comments>http://www.stockbloghub.com/2009/04/20/ibm-stock-market-news-for-april-20-2009-market-news/5769#comments</comments>
		<pubDate>Mon, 20 Apr 2009 20:06:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Coca-Cola Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[General Motors Corporation]]></category>
		<category><![CDATA[GM]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machine]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Co]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corp.]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5769</guid>
		<description><![CDATA[US stocks ended another week on a winning note as earnings reports, although not great by normal standards, and a consumer sentiment survey indicated the economy and financial markets are showing signs of stabilization.  The Dow Jones industrial average closed the week up 47.95, or 0.6%, at 8,131.33. The Standard &#38; Poor&#8217;s 500 index rose 13.04, or 1.5%, to 869.60.  The tech-heavy Nasdaq rose 20.53, or 1.2%, to 1,673.07.  The broad-based S&#38;P 500, which recorded its steepest six-week gain since 1938, is now up 29% since hitting its 12-year nadir on March 9. As risk appetite grew treasuries declined, taking the yield on the 2-year to 0.981% and the 10-year to 2.953% as prices fell 4/32 and 30/32, respectively on Friday. The Vix, CBOE&#8217;s volatility index, declined 2.59 points over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/20/ibm-stock-market-news-for-april-20-2009-market-news/5769/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WYE) Biotech Industry &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310</link>
		<comments>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310#comments</comments>
		<pubDate>Fri, 13 Mar 2009 22:00:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4310</guid>
		<description><![CDATA[OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets to weather the current market turmoil and can generate revenue from product sales. Investors in large biotechnology companies worth more than $1 billion have preserved much of their wealth. Smaller biotech companies, particularly those still in development stage, meanwhile, are under severe strain as the global economic slump cuts into sales and their ability to raise fresh cash to fund research. As we expected, the M&#38;A spree has continued in the first three months of this year. Following the acquisition of Wyeth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

